NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) announced today that its Canadian subsidiary, Forest Laboratories Canada Inc. has received a Notice of Compliance from Health Canada for BYSTOLIC® (nebivolol) tablets, a once daily beta blocker for the treatment of hypertension. “We are pleased that Health Canada has granted approval for BYSTOLIC. This is an important milestone for Forest, as it is the first product approved for our newly established Canadian subsidiary. We look forward to bringing additional innovative Forest products to the Canadian market” "We are pleased that Health Canada has granted approval for BYSTOLIC. This is an important milestone for...
0 Responses to Forest Laboratories, Inc. Announces Health Canada Approval of BYSTOLIC for the Treatment of Hypertension